Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2007 Sep;51(9):3445-8.
doi: 10.1128/AAC.00559-07. Epub 2007 Jul 9.

Characterization of a daptomycin-nonsusceptible vancomycin-intermediate Staphylococcus aureus strain in a patient with endocarditis

Kathleen Julian  1 , Klaudia Kosowska-Shick, Cynthia Whitener, Martin Roos, Harald Labischinski, Aileen Rubio, Leslie Parent, Lois Ednie, Laura Koeth, Tatiana Bogdanovich, Peter C Appelbaum
Affiliations

Characterization of a daptomycin-nonsusceptible vancomycin-intermediate Staphylococcus aureus strain in a patient with endocarditis

Kathleen Julian et al. Antimicrob Agents Chemother. 2007 Sep.

Abstract

We analyzed the emergence of daptomycin nonsusceptibility in a patient with persistent vancomycin-intermediate Staphylococcus aureus (VISA) bacteremia. The daptomycin-nonsusceptible VISA's cell wall demonstrated a reduction in muramic acid O-acetylation, a phenotypic parameter not previously reported for VISA; some isolates also contained a single point mutation in the mprF gene.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Appelbaum, P. C., A. Philippon, M. R. Jacobs, S. K. Spangler, and L. Gutmann. 1990. Characterization of β-lactamases from non-Bacteroides fragilis group Bacteroides spp. belonging to seven species and their role in β-lactam resistance. Antimicrob. Agents Chemother. 34:2169-2176. - PMC - PubMed
    1. Clinical and Laboratory Standards Institute. 2006. Performance standards for antimicrobial susceptibility testing; 16th informational supplement. CLSI/NCCLS M100-S16. Clinical and Laboratory Standards Institute, Wayne, PA.
    1. Cui, L., E. Tominaga, H. M. Neoh, and K. Hiramatsu. 2006. Correlation between reduced daptomycin susceptibility and vancomycin resistance in vancomycin-intermediate Staphylococcus aureus. Antimicrob. Agents Chemother. 50:1079-1082. - PMC - PubMed
    1. Fowler, V. G., Jr., H. W. Boucher, G. R. Corey, E. Abrutyn, A. W. Karchmer, M. E. Rupp, D. P. Levine, H. F. Chambers, F. P. Tally, G. A. Vigliani, C. H. Cabell, A. S. Link, I. DeMeyer, S. G. Filler, M. Zervos, P. Cook, J. Parsonnet, J. M. Bernstein, C. S. Price, G. N. Forrest, G. Fatkenheuer, M. Gareca, S. J. Rehm, H. R. Brodt, A. Tice, S. E. Cosgrove, and the S. aureus Endocarditis and Bacteremia Study Group. 2006. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N. Engl. J. Med. 355:653-665. - PubMed
    1. Fridkin, S. K., J. Hageman, L. K. McDougal, J. Mohammed, W. R. Jarvis, T. M. Perl, F. C. Tenover, and the Vancomycin-Intermediate Staphylococcus aureus Epidemiology Study Group. 2003. Epidemiological and microbiological characterization of infections caused by Staphylococcus aureus with reduced susceptibility to vancomycin, United States, 1997-2001. Clin. Infect. Dis. 36:429-439. - PubMed

MeSH terms

LinkOut - more resources